IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2023

 Aggregated presentation by day and by market

Name of issuerIdentification code of issuer (Legal Entity Identifier)Day of transactionIdentification code of financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares *Market (MIC Code)
IPSEN549300M6SGDPB4Z94P1112/06/2023FR0010259150260111.72AQEU
IPSEN549300M6SGDPB4Z94P1112/06/2023FR0010259150960111.40CEUX
IPSEN549300M6SGDPB4Z94P1112/06/2023FR0010259150588111.57TQEX
IPSEN549300M6SGDPB4Z94P1112/06/2023FR00102591502,892111.57XPAR
IPSEN549300M6SGDPB4Z94P1113/06/2023FR0010259150808111.08AQEU
IPSEN549300M6SGDPB4Z94P1113/06/2023FR00102591501,143111.13CEUX
IPSEN549300M6SGDPB4Z94P1113/06/2023FR0010259150669111.22TQEX
IPSEN549300M6SGDPB4Z94P1113/06/2023FR00102591503,430111.15XPAR
IPSEN549300M6SGDPB4Z94P1114/06/2023FR0010259150659111.15AQEU
IPSEN549300M6SGDPB4Z94P1114/06/2023FR00102591501,148111.04CEUX
IPSEN549300M6SGDPB4Z94P1114/06/2023FR0010259150398111.14TQEX
IPSEN549300M6SGDPB4Z94P1114/06/2023FR00102591504,195111.03XPAR
IPSEN549300M6SGDPB4Z94P1115/06/2023FR00102591501,034110.72AQEU
IPSEN549300M6SGDPB4Z94P1115/06/2023FR00102591501,504110.67CEUX
IPSEN549300M6SGDPB4Z94P1115/06/2023FR0010259150584110.65TQEX
IPSEN549300M6SGDPB4Z94P1115/06/2023FR00102591504,678110.57XPAR
IPSEN549300M6SGDPB4Z94P1116/06/2023FR0010259150210111.17AQEU
IPSEN549300M6SGDPB4Z94P1116/06/2023FR0010259150387111.89CEUX
IPSEN549300M6SGDPB4Z94P1116/06/2023FR0010259150223112.19TQEX
IPSEN549300M6SGDPB4Z94P1116/06/2023FR00102591501,947112.10XPAR
       
* Two-digit rounding after the decimal TOTAL27,717111.13 



Attachment



EN
20/06/2023

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone...

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be closed. The investigational medicinal product (fidrisertib) was generally well tolerated, with no safety concerns in the trial. “These results are ...

34m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients a...

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP) PARIS, FRANCE – 19 décembre 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui que l'essai pivotal de Phase II FALKON n'a pas atteint son critère principal, à savoir la réduction du volume de formation anormale de nouvelle matière osseuse (ossification hétérotopique ou OH) chez l’adulte et l’enfant atteints de fibrodysplasie ossifiante progressive (FOP), par rapport au placebo, en conséquence, l'étude sera clôturée. Le mé...

34m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi...

Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi son portefeuille de produits oncologiques PARIS, FRANCE, 15 DECEMBRE 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd’hui avoir finalisé l'acquisition d'ImCheck Therapeutics, une société privée française de biotechnologie pionnière dans le domaine des thérapies d’immuno-oncologie de nouvelle génération. A propos d’Ipsen Nous sommes un groupe biopharmaceutique mondial focalisé sur la mise au point de médicaments innovants pour les patients dans trois domaines thérapeutiques : l’Oncologie, les Maladies Rare...

December 15, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncolog...

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 year...

December 15, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025 Aggregated presentation by day and by marketStatement of transactions in own shares from December 1st to December 05th 2025       Name of the issueIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1101/12/2025FR0010259150200124,05000AQEUIPSEN549300M6SGDPB4Z94P1101/12/2025FR0010259150831123,81540CEUXIPSEN549300M6SGDPB4Z94P1101/12/2025FR0...

December 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch